Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B14 | Q9BPX1 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 8/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295319 | 1.00 | HSD17B14 (0.48) | HSD17B14ROCK2SCDSCD5HSD11B1 | |
| SCHEMBL4294496 | 1.00 | HSD17B14 (0.48) | HSD17B14ROCK2SCDSCD5HSD11B1 | |
| SCHEMBL4299801 | 0.97 | PRKCQ (0.46) | HSD17B14ROCK2SCDSCD5HSD11B1 | |
| SCHEMBL4299796 | 0.97 | PRKCQ (0.46) | HSD17B14ROCK2SCDSCD5HSD11B1 | |
| SCHEMBL4299325 | 0.89 | HSP90AA1 (0.47) | HSD17B14HSD11B1PRKCQ | |
| SCHEMBL4304799 | 0.89 | HSP90AA1 (0.47) | HSD17B14HSD11B1PRKCQ | |
| SCHEMBL4299319 | 0.89 | HSP90AA1 (0.47) | HSD17B14HSD11B1PRKCQ | |
| SCHEMBL13755707 | 0.88 | HSD17B14 (0.43) | HSD17B14ROCK2SCDSCD5HSD11B1 | |
| SCHEMBL4295295 | 0.85 | PRKCA (0.46) | HSD17B14ROCK2SCDSCD5HSD11B1 | |
| SCHEMBL4301810 | 0.85 | HSD17B14 (0.46) | HSD17B14ROCK2SCD5HSD11B1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009098576-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | PFIZER INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | HSD17B14 2214/4885ROCK2 2849/4885SCD 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.